CENTOGENE
THE RARE DISEASE COMPANY

CentoGenome®

THE COMPLETE DIAGNOSTIC SOLUTION

See diagnostics in a new way
with **whole genome sequencing**

CentoGenome® KEY BENEFITS

Highest diagnostic rate **>45%**

- Highly effective diagnostic tool providing genetic diagnosis in > 45% of the cases*
- Reliable detection of virtually all disease-causing genetic variants (e.g., single-nucleotide variants, small insertion/deletions, and copy number variants)
- Increased probability of timely diagnosis (e.g., directly identify known and potentially disease-causing variants not covered by exome sequencing or microarrays) and suitable clinical management (e.g., appropriate treatment options, recurrence risk assessment)
- Automatic 'life-time' reclassification of reported variants and easier reanalysis of the securely stored patient's genome data

CentoGenome® HIGHEST QUALITY AND COMPETENCY IN WGS INTERPRETATION

- Nearly complete and uniform coverage of the entire coding and non-coding regions of the genome (~99% of the genome is covered at >10X; mean depth >30X)
- Confirmation of any lower quality variants before reporting
- Fist-in-class conclusive clinical reports with clear actionable results, recommendations and follow up steps.
- Powered by CentoMD® – the world's largest mutation database of rare genetic diseases, which guarantees the best diagnostic yields

CentoGenome® ESPECIALLY RECOMMENDED FOR PATIENTS WITH:

- Heterogeneous phenotypes
- Unclear or atypical clinical symptoms
- Long list of prior differential diagnoses
- Exhausted other genetic testing options

Save valuable time by using our expertise to diagnose your patients

V3.2eng_March2019

Contact Details

Phone: +49 (0)381 80 113 - 416
Email: customer.support@centogene.com
www.centogene.com

CLIA #99D2049715
Following GLP and GMP guidelines.

CAP ACCREDITED COLLEGE of AMERICAN PATHOLOGISTS

ISO 15189 CAP ACCREDITED COLLEGE of AMERICAN PATHOLOGISTS

*Data on file at CENTOGENE and results comparable to published work (e. g., Stavropoulos et al., 2016, PMID: 28567303; Bowling et al., 2017, PMID: 28567303; Lionel et al. 2018, PMID: 28771251; Clark et al. 2018, PMID: 30002876; Farnaes et al. 2018, PMID: 29644095).